<?xml version="1.0" encoding="UTF-8"?>
<p>The prevalence of new-onset heart failure during COVID-19 associated hospitalization was reported to be 23% and was more common in nonsurvivors compared to survivors (52% vs. 12%, 
 <italic>p</italic> &lt; 0.0001) [
 <xref rid="B7-jcm-09-01407" ref-type="bibr">7</xref>]. Moreover, the first description of critically ill patients from the United States indicated that 33% of the ICU patients developed cardiomyopathy [
 <xref rid="B50-jcm-09-01407" ref-type="bibr">50</xref>]. Most recently, Fried et al. described three cases of COVID-19 infection with acute systolic heart failure [
 <xref rid="B30-jcm-09-01407" ref-type="bibr">30</xref>], suggesting that isolated myocarditis, myocarditis secondary to cytokine storm, stress-cardiomyopathy, and hypoxemia on underlying cardiovascular disease could be considered as potential mechanisms of left ventricular dysfunction. However, given the scarce availability of data regarding this topic, it remains unclear whether the acute heart failure following COVID-19 is mainly due to exacerbation of pre-existing cardiac dysfunction or new-onset cardiomyopathy.
</p>
